

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/245249 A1

- (51) **International Patent Classification:**
A61K 39/00 (2006.01) *A61K 31/41* (2006.01)
- (21) **International Application Number:**
PCT/EP2021/065037
- (22) **International Filing Date:**
04 June 2021 (04.06.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/035,104 05 June 2020 (05.06.2020) US
- (71) **Applicants:** **TESSA THERAPEUTICS LTD.** [SG/SG]; 138 Depot Road, #07-01, Singapore 109683 (SG). **THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL** [US/US]; 109 Church Street, Chapel Hill, North Carolina 27516 (US).
- (71) **Applicant (for LS only):** **CLEGG, Richard** [GB/GB]; City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB).
- (72) **Inventors:** **MYO, Aung**; 138 Depot Road, #07-01, Singapore 109683 (SG). **HORAK, Ivan David**; 138 Depot Road, #07-01, Singapore 109683 (SG). **SERODY, Jonathan**; c/

o The University of North Carolina at Chapel Hill, 109 Church Street, Chapel Hill, North Carolina 27516 (US). **DOTTI, Gianpiero**; c/o The University of North Carolina at Chapel Hill, 109 Church Street, Chapel Hill, North Carolina 27516 (US). **SAVOLDO, Barbara**; c/o The University of North Carolina at Chapel Hill, 109 Church Street, Chapel Hill, North Carolina 27516 (US).

(74) **Agent:** **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) **Title:** TREATMENT OF CD30-POSITIVE CANCER




Figure 2

(57) **Abstract:** Methods for treating a CD30-positive cancer in a subject are disclosed, wherein the methods comprise administering a lymphodepleting chemotherapy and CD30-specific chimeric antigen receptor (CAR)-expressing cells.

[Continued on next page]

WO 2021/245249 A1

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*